[ad_1]
United Arab Emirates – Doctors at the Abu Dhabi Stem Cell Center (ADSCC), part of the PureHealth Group, performed the region’s first successful bone marrow transplant on a patient with multiple sclerosis (MS).
A bone marrow transplant performed under the Abu Dhabi Bone Marrow Transplantation (AD-BMT) program was a major achievement, demonstrating significant advances in cell therapy and regenerative medicine in the treatment of a range of diseases, including cancer and disorders of the immune system.
Earlier this month, doctors at ADSCC performed the region’s first autologous hematopoietic stem cell transplant (AHSCT) on a multiple sclerosis patient, after which the patient reported an improvement in his overall condition. Developed by ADSCC, the therapy aims to “reset” a person’s immune system and could be used in patients with relapsing forms of multiple sclerosis.
Support for Covid-19 patients
The transplant’s success follows ADSCC’s pioneering work in providing Covid-19 patients during the pandemic, for which World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus praised the center for its use of cutting-edge Covid-19 treatments. These include UAECell19, launched by ADSCC in 2020, to treat thousands of Covid-19 patients to help restore lung capacity through stem cell therapy.
ADSCC’s Abu Dhabi Bone Marrow Transplantation (AD-BMT) Program was established in 2020 to provide autologous and allogeneic HSCT to adults and children as a comprehensive program and implement different forms of cell therapy such as adoptive cell transfer.
ADSCC’s AD-BMT program team worked with the center’s neurology team to treat MS patients under the leadership of AD-BMT program director Dr. Fatima Al Kaabi.
Expand world-class capabilities
Commenting on the landmark treatment, Dr Al Kaabi said: “At ADSCC we are committed to ensuring that the AD-BMT program meets the highest standards of quality and patient satisfaction throughout all steps of the process including treatment, aftercare and follow-up . With this new therapy, we expand our world-class capabilities, which represent hope and aim to improve the quality of life for everyone.”
Dr Yendry Ventura, CEO of ADSCC, said: “We are very proud of the Abu Dhabi Stem Cell Center’s achievement, becoming the first center in the region to perform BMT on MS patients. We are very proud of the treatment of life. We are grateful for the vision of the UAE’s wise leadership and the support of PureHealth management for making this possible.”
Shaista Asif, Group Chief Operating Officer, PureHealth Group, said: “The timing of a revolutionary bone marrow transplant for an MS patient in the UAE could not be more opportune as we mark five decades of progress in the UAE’s field. Wise in the UAE And under visionary leadership, PureHealth and its subsidiaries are committed to raising the benchmark for healthcare excellence to drive efficiencies across the healthcare value chain. In line with our commitment to longevity science, this is geared toward improving the average healthy lifespan in the country. An important step forward.”
standard of care
According to the 2019 updated European Blood and Marrow Transplantation (EBMT) and American Society for Blood and Marrow Transplantation (ASBMT) guidelines, the AHSCT procedure performed by the ADSCC is a “standard of care” rather than a mere “clinical choice”, reviewed Clinical evidence of AHSCT in MS patients.
It is an established and effective treatment for highly active relapsing-remitting multiple sclerosis (RRMS) in which at least one disease-modifying treatment has failed. EBMT promotes scientific excellence to further improve stem cell transplant outcomes, while ASBMT works to advance scientific and clinical care for patients in need of blood and bone marrow transplants.
ADSCC continues to deliver advanced treatments such as extracorporeal photofractionation therapy in the UAE and is the only center under the PureHealth Group with two open clinical trials. To date, ADSCC under the AD-BMT program has treated 13 cancer patients and one MS patient.
Copyright 2022 Al Hilal Publishing and Marketing Group Courtesy of SyndiGate Media Inc. (Syndicate Information).
[ad_2]
Source link